Bibliografia do art. prof. P. Claytona „ZbL“ 2/2022

prof. P. Clayton Naturalna odporność pozwala przetrwać COVID

Bibliografia:

1. Antibiotic /Antimicrobial Resistance. 2019 AR Threats Report. https://www.cdc.gov/DrugResistance/biggest-threats.html
2. Weigand MR, Peng Y, Cassiday PK, Loparev VN, Johnson T, Juieng P, Nazarian EJ, Weening K, Tondella ML, Williams MM. Complete Genome Sequences of Bordetella pertussisIsolates with Novel Pertactin-Deficient Deletions. Genome Announc. 2017 Sep 14;5(37):e00973-17.
3. Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, McGee L, von Gottberg A, Song JH, Ko KS, Pichon B, Baker S, Parry CM, Lambertsen LM, Shahinas D, Pillai DR, Mitchell TJ, Dougan G, Tomasz A, Klugman KP, Parkhill J, Hanage WP, Bentley SD. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011 Jan 28;331(6016):430-4.
4. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017 Sep;7(3):339-348.
5. Powles SB, Yu Q. Evolution in Action: Plants Resistant to Herbicides. Ann Rev Plant Biol 61 (2010), 317-347
6. Manalil S, Busi R, Renton M, Powles SB. Rapid Evolution of Herbicide Resistance by Low Herbicide Dosages. Weed Sci 2011 59:210-217
7. Aktar MW, Sengupta D, Chowdhury A. (2009). Impact of pesticides use in agriculture: their benefits and hazards.   Interdisciplinary toxicology, 2(1), 1–12.
8. Barclay VC, Sim D, Chan BH, Nell LA, Rabaa MA, Bell AS, Anders RF, Read AF. The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi. PLoS Biol. 2012;10(7):e1001368.
9. McKimm-Breschkin JL. Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1(Suppl 1):25-36.
10. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. 2004 Oct;53(10):1499-503.
11. Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, Abeles SR, Torriani FJ. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. N Engl J Med. 2021 Sep 1. doi: 10.1056/NEJMc2112981. Epub ahead of print.
12. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, Cohen D, Muhsen K, Chodisk G, Patalon T. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv doi: https://doi.org/10.1101/2021.08.24.21262415
13. Ivanova EN, Devlin JC, Buus TB, Koide A, Cornelius A, Samanovic MI, Herrera A, Zhang C, Desvignes L, Odum N, Ulrich R, Mulligan MJ, Koide S, Ruggles KV, Herati RS, Koralov SB. Discrete immune response signature to SARS-CoV-2 mRNA vaccination versus infection. medRxiv [Preprint]. 2021 Apr 21:2021.04.20.21255677.
14. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, Haile A, Klebert MK, Pusic I, O’Halloran JA, Presti RM, Ellebedy AH. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Res Sq [Preprint]. 2020 Dec 31:rs.3.rs-132821.
15. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah PA, Low JG, Tan YJ, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. 2020 Aug;584(7821):457-462.
16. Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Necessity of COVID-19 vaccination in previously infected individuals. medRxiv [Preprint]. doi:  https://doi.org/10.1101/2021.06.01.21258176
17. Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, Norwood C, Nyhoff LE, Edara VV, Floyd K, De Rosa SC, Ahmed H, Whaley R, Patel SN, Prigmore B, Lemos MP, Davis CW, Furth S, O’Keefe J, Gharpure MP, Gunisetty S, Stephens KA, Antia R, Zarnitsyna VI, Stephens DS, Edupuganti S, Rouphael N, Anderson EJ, Mehta AK, Wrammert J, Suthar MS, Ahmed R, McElrath MJ. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. medRxiv [Preprint]. 2021 Jun 18:2021.04.19.21255739.
18. Sureshchandra S, Lewis SA, Doratt B, Jankeel A, Ibraim I, Messaoudi I. Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine. bioRxiv (Preprint). doi: https://doi.org/10.1101/2021.07.14.452381
19. Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR. mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B.1.1.7 and B.1.351 variants but differ in longevity and homing properties depending on prior infection status. bioRxiv doi: https://doi.org/10.1101/2021.05.12.443888
20. O Murchu E, Byrne P, Carty PG, De Gascun C, Keogan M, O’Neill M, Harrington P, Ryan M. Quantifying the risk of SARS-CoV-2 reinfection over time. Rev Med Virol. 2021 May 27:e2260. doi: 10.1002/rmv.2260. Epub ahead of print.
21. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, Ayoub HH, Al Kanaani Z, Al Kuwari E, Butt AA, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Al Khal A, Bertollini R. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. 2021 May;35:100861.
22. Goldberg Y, Mandel M, Woodbridge Y, Fluss R, Novikov I, Yaari R, Ziv A, Freedman L, Huppert A. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel. medRxiv prepreint doi: https://doi.org/10.1101/2021.04.20.21255670
23. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, Park DW, Park SH, Jeong HW, Choi WS, Shin EC. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat Commun. 2021 Jun 30;12(1):4043.
24. Cho A and 25 others. Antibody Evolution after SARS-CoV-2 mRNA Vaccination. bioRxiv Preprint. doi: https://doi.org/10.1101/2021.07.29.454333
25. Camara C, Lozano-Ojalvo D, Lopez-Granados E, Paz-Artal E, Pion M, Correa-Rocha R, OrtizA, Lopez-Hoyos M, Iribarren ME, Portoles J, Portoles P, Perez-Olmeds M, Oteo J, Berin ZC, Guccione E, Bertoletti A, Ochando JK. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals. bioRxiv Preprint. doi: https://doi.org/10.1101/2021.03.22.436441
26. Israel A, Shenhar Y, Green I, Merzon E, Golan-Cohen A, Schäffer AA, Ruppin E, Vinker S, Magen E. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. medRxiv [Preprint]. 2021 Aug 21:2021.08.19.21262111.
27. https://www.zerohedge.com/covid-19/israels-virus-czar-tells-citizens-prepare-eventual-4th-shot
28. https://www.timesofisrael.com/virus-czar-calls-to-begin-readying-for-eventual-4th-vaccine-dose/
29. https://www.news.com.au/lifestyle/health/health-problems/nsw-residents-told-to-expect-covid19-booster-shots-indefinitely/news-story/abda9fcf5d5344c6c8ed22bc5d939b16
30. https://www.worldometers.info/coronavirus/
31. Pascarella S, Ciccozzi M, Bianchi M, Benvenuto D, Cauda R, Cassone A. Cutting epitopes to survive: the case of lambda variant. doi:https://doi.org/10.1101/2021.08.14.456353
32. Riemersma KK, Grogan BE, Kita-Yarboro A, Halfmann PJ, Segaloff HE, Kocharian A, Florek KR, Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O’Connor DH, Friedrich TC, Grande KM. Shedding of Infectious SARS-CoV-2 Despite Vaccination. medRxiv Preprint https://doi.org/10.1101/2021.07.31.21261387
33. https://www.theblaze.com/op-ed/horowitz-no-this-is-not-an-epidemic-of-the-unvaccinated-its-a-pandemic-of-censored-early-treatment
34. Riemersma KK, Grogan BE, Kita-Yarbro A, Jeppson GE, O’Connor DH, Friedrich TC, Grande KM. Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant. medRxiv Preprint. doi: https://doi.org/10.1101/2021.07.31.21261387
35. Geoghegan JL, Senior AM, Di Giallonardo F, Holmes EC. Virological factors that increase the transmissibility of emerging human viruses.  Natl Acad. Sci. USA113, 4170–4175 (2016).
36. Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-Brown SW, Nair VK. Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens. PLoS Biol. 2015 Jul 27;13(7):e1002198.
37. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
38. https://www.precisionvaccinations.com/covid-19-vaccine-related-fatalities-updated
39. Collignon P, Doshi P, Jefferson T. Child influenza vaccination. Ramifications of adverse events in children in Australia. 2010 Jun 9;340:c2994.
40. Institute of Medicine (US) Board on Health Promotion and Disease Prevention. Vaccine Safety Forum: Summaries of Two Workshops. Washington (DC): National Academies Press (US); 1997. Improving Detection of and Response to Adverse Events.

https://www.ncbi.nlm.nih.gov/books/NBK232983/

41. Cunningham A. Underreporting Vaccine Adverse Effects. Rapid response to BMJ 2010;340:c2994
42. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England, Technical Briefing 20. Table 5. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf
43. https://www.bbc.com/news/health-55274833
44. https://www.idahostatesman.com/news/local/community/boise/article253556914.html
45. https://drive.google.com/file/d/17jVCBwrDJ-4Ktf6G-AOFdxcXKsj2MTg7/view
46. Oberhardt V, Luxenburger H, Kemming J and 30 others.Rapid and stable mobilization of CD8⁺ T cells by SARS-CoV-2 mRNA vaccine.  Nature (2021). https://doi.org/10.1038/s41586-021-03841-4
47. Bryant A, Lawrie TA, Fordham EJ. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021. Am J Ther. 2021 Aug 18;28(5):e573–6.
48. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021 Jun 21;28(4):e434-e460.
49. Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Am J Ther. 2021 Apr 22;28(3):e299-e318.
50. Winchester S, John S, Jabbar K, John I. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect. 2021 Aug;83(2):237-279.
51. Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, Pegu A, Oloniniyi OK, Henry AR, Darko S, Narpala SR, Hatcher C, Martinez DR, Tsybovsky Y, Phung E, Abiona OM, Antia A, Cale EM, Chang LA, Choe M, Corbett KS, Davis RL, DiPiazza AT, Gordon IJ, Hait SH, Hermanus T, Kgagudi P, Laboune F, Leung K, Liu T, Mason RD, Nazzari AF, Novik L, O’Connell S, O’Dell S, Olia AS, Schmidt SD, Stephens T, Stringham CD, Talana CA, Teng IT, Wagner DA, Widge AT, Zhang B, Roederer M, Ledgerwood JE, Ruckwardt TJ, Gaudinski MR, Moore PL, Doria-Rose NA, Baric RS, Graham BS, McDermott AB, Douek DC, Kwong PD, Mascola JR, Sullivan NJ, Misasi J. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. 2021 Aug 13;373(6556):eabh1766.